CME regulator issues plan for shoring up oversight
The regulatory body, the Accreditation Council for CME (ACCME), will also consider imposing tougher penalties on accredited providers who break the rules and more closely scrutinizing content for commercial bias. The enhancements were contained in a five-part list of areas to be studied, issued late Friday afternoon by ACCME chief executive Murray Kopelow, MD.
The plan comes in response to perceived weakness in ACCME's rules of commercial support—the rules for ensuring the independence of educational activities—and the group's compliance-checking system. The Senate Finance Committee blasted both in its April report on the use of educational grants by drug firms.
The list of possible steps, which ACCME calls an “action plan,” was drafted by the group at its July board meeting as it felt pressure to appear responsive to the Senate report. The fact that the plan contains a variety of proposed steps highlights the difficulty in getting to the root of the Senate concerns.
“The big problem is nobody knows,” said Van Harrison, PhD, an ACCME board member and director of the Office of CME at the
The response will have to occur in multiple ways and address two main areas. First involves dealing with the Senate's complaint of very slow turnaround times to correct problems. It can take years after a non-compliant activity for the group to impose a penalty. Second involves the need for stronger monitoring of specific providers and enforcement of the current standards.
Cost-effectiveness will be another challenge, as Sens. Baucus (D-MT) and Grassley (R-IA), the ranking members of the Senate Finance Committee, will be loathe to add a whole new layer of costs to the healthcare system. Currently ACCME inspects and audits only a percentage of activities that are provider certified; the Senate said that that's not enough. Kopelow's plan shows the ACCME is committed to beefing up its monitoring but needs to do so in a way that doesn't increase costs for everyone.
“That's going to be tough. At every CME activity, you're going to have a physician complain about something,” said Stephen Lewis, who headed an accredited medical education company for several years.
As far as taking measures to improve the integrity of CME, the Senate report was quite complimentary to actions taken by the pharmaceutical manufacturers, most of which have moved education out of the marketing department over the last few years. Nevertheless, among other steps ACCME said it will look at are alternate funding models, like pooled funding and limits.
This will involve “discussions on the value, or impact, of no commercial support,” Kopelow wrote. While receiving financial support from industry doesn't mean content or faculty is influenced, “the future role of industry in CME, including that of a funder, will be evaluated in the context of independence,” he noted.
In the months since the senators issued their report, ACCME released data showing that drug company funding accelerated 8% last year compared to 2005 to nearly $1.2 billion. Funding to medical schools and societies increased faster than funding to medical education and communication companies (MECCs), a possible sign that pharma wants to be seen writing checks to providers that appear safer from a compliance standpoint (although compliance data show MECCs are just as compliant with ACCME rules on handling commercial support, if not moreso, than these other groups).
Additional education for physician learners, faculty, drug firms and providers are also among the steps being explored, as is collaboration with other organizations to help ensure bias-free CME. The ACCME staff must now develop a narrower list of priorities, which the board will discuss when it meets next November.
“The boundaries between promotion and CME need to be clarified for all participants in the system,” Kopelow wrote.